News

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on ...
BridgeBio Pharma, Inc.: BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, today ...
Kalkine Media3d
How Is BridgeBio Pharma Advancing Treatments in Genetic Diseases and...
Highlight,Sector Focus,: BridgeBio Pharma operates in the biopharmaceutical sector, with a focus on genetic conditions and oncology.,Insider Actions,: Notable insider share transactions have been ...
BridgeBio price target raised to $53 from $49 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on BridgeBio (BBIO) to $53 from $49 and keeps a Buy rating on the ...
Mena FN8d
Bridgebio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
(MENAFN- GlobeNewsWire - Nasdaq) PALO ALTO, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the“Company”), a ...
Business Insider8d
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage ...
STAT12d
BridgeBio CEO: Congress must renew a popular, bipartisan FDA program benefiting sick kids
In Washington, even widely hailed programs with bipartisan support — like the rare pediatric disease priority review voucher ...
Investing9d
Piper Sandler maintains Overweight rating on BridgeBio Pharma stock
Thursday, Piper Sandler reiterated an Overweight rating on BridgeBio Pharma (NASDAQ:BBIO) with a price target of $46.00, aligning with the broader Wall Street sentiment. According to InvestingPro ...